WO2023084311 - OLAPARIB HYDROXYBENZOIC ACID COCRYSTALS AND THEIR PHARMACEUTICAL USE
National phase entry:
Publication Number
WO/2023/084311
Publication Date
19.05.2023
International Application No.
PCT/IB2022/000711
International Filing Date
10.11.2022
Title **
[English]
OLAPARIB HYDROXYBENZOIC ACID COCRYSTALS AND THEIR PHARMACEUTICAL USE
[French]
CO-CRISTAUX D'ACIDE HYDROXYBENZOÏQUE D'OLAPARIB ET LEUR UTILISATION PHARMACEUTIQUE
Applicants **
NUFORMIX TECHNOLOGIES LIMITED
6th Floor, 60 Gracechurch Street
London EC3V 0HR, GB
Inventors
HOLLAND, Joanne
20B Pages Close, Histon
Cambridge, Cambridgeshire CB24 9HF, GB
EBERLIN, Alex
6 Scholars Walk
Cambridge CB4 1EJ, GB
Priority Data
63/277,773
10.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1799 | |
| EPO | Filing, Examination | 9976 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 7910 |
Total: 20849 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention also relates to pharmaceutical compositions containing an olaparib hydroxybenzoic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP).[French]
L'invention concerne de nouveaux co-cristaux d'olaparib : acide hydroxybenzoïque 1:1. L'invention concerne également de nouveaux co-cristaux d'olaparib : acide hydroxybenzoïque 2 : 1, et pouvant ne pas contenir d'eau (anhydres) ou pouvant éventuellement être hydratés. L'invention concerne également des compositions pharmaceutiques contenant le co-cristal d'acide hydroxybenzoïque d'olaparib selon l'invention et un véhicule pharmaceutiquement acceptable. Les co-cristaux d'acide hydroxybenzoïque d'olaparib selon l'invention peuvent être utiles pour le traitement de maladies qui bénéficient de l'inhibition de la poly (ADP-ribose) polymérase (PARP).